Chronic myeloid leukaemia vaccine

Drug Profile

Chronic myeloid leukaemia vaccine

Alternative Names: Ablvax; Chronic myelogenous leukaemia vaccine; CMLVAX 100; CMLVAX 500; Multivalent BCR-ABL oncogene product fusion peptide vaccine; VAX 100

Latest Information Update: 23 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Breakthrough Therapeutics
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Chronic myeloid leukaemia

Most Recent Events

  • 12 Jan 2006 Data presented at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH-2005) have been added to the adverse events and Cancer therapeutic trials section ,
  • 04 Mar 2005 The vaccine has been licensed to Breakthrough Therapeutics
  • 04 Mar 2005 Data from a media release have been added to the Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top